LSV International ACWI Ex US (S:0P0000TQSK)
51.64
+1.21
(+2.40%)
USD |
Nov 30 2025
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Fixed Income Style | None |
| Broad Asset Class | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Annual Total Returns Versus Peers
As of December 31, 2025.
Asset Allocation
| Type | % Net |
|---|---|
| Cash | -- |
| Stock | -- |
| Bond | -- |
| Convertible | -- |
| Preferred | -- |
| Other | -- |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Novartis AG | 2.14% | 138.00 | -0.32% |
| UBS Group AG | 1.20% | 46.32 | -0.43% |
| HSBC Holdings Plc | 1.14% | 14.75 | -7.38% |
| Deutsche Bank AG | 1.07% | 38.64 | -0.44% |
| Imperial Brands Plc | 1.01% | 41.83 | -1.69% |
| GSK Plc | 0.98% | 24.60 | 6.96% |
| Banco Santander SA | 0.88% | 12.43 | 5.91% |
| Tesco Plc | 0.87% | 6.20 | 3.51% |
| Alibaba Group Holding Ltd. | 0.81% | 18.76 | -0.27% |
| BNP Paribas SA | 0.79% | 95.66 | 0.73% |
Fees & Availability
| Fees | |
| Negotiable Fee | -- |
| Maximum Management Fee | -- |
| Prospectus Custodian Fee | -- |
| Purchase Details | |
| Open to New Investors | -- |
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Fixed Income Style | None |
| Broad Asset Class | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Fundamentals
| General | |
| Number of Holdings | -- |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| Number of Equity Holdings | -- |
Fund Details
| Key Dates | |
| Inception Date | -- |
| Attributes | |
| Socially Responsible Fund | -- |